Clinical Trials Browser

OTHER × ibrutinib × Dermatologic × Clear all

NCT03021460 2026-01-20

Pembrolizumab and Ibrutinib in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery

Phase 1 Active not recruiting

Melanoma